Biolexis Therapeutics Inc.

Biotechnology · LEHI, UT

BiotechnologySEC Form D

Biolexis Therapeutics Inc. filed a Form D with the U.S. Securities and Exchange Commission on June 3, 2026, reporting $1,600,000 raised toward a $12,000,000 offering.

Incorporated in Delaware and based in LEHI, UT, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Biolexis Therapeutics Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Tyler HartmannExecutive Officer
  • David J. BearssDirector
  • Hariprasad VankayalapatiDirector
  • James N. ClarkeDirector
  • Anthony SteveDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$10.0MRaised

Senti Biosciences Holdings, Inc.

BiotechnologySouth San Francisco, CA
May 20, 2026View SEC Form D
Biolexis Therapeutics Inc. raised $1.6M — SEC Form D